IGF1 and risk of additional breast cancer in the WHEL study

Wael K. Al-Delaimy, Shirley W. Flatt, Loki Natarajan, Gail A. Laughlin, Cheryl L. Rock, Ellen B Gold, Bette J. Caan, Barbara A. Parker, John P. Pierce

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

IGF1, IGF-binding protein-3 (IGFBP-3), IGFBP-1, insulin, leptin, and adiponectin have been inconsistently associated with breast cancer incidence. We explore how these factors are related to breast cancer recurrence and how tamoxifen treatment is related to IGF1 levels among breast cancer survivors in the Women's Healthy Eating and Living (WHEL) study. A nested case-control design was used to match breast cancer cases (who had an additional breast cancer event) to controls. Baseline blood samples from 510 matched cases and controls were analyzed for IGF1 levels; a subset of 188 pairs were analyzed for five other hormones and binding proteins. Median follow-up was 7.3 years. Matching was on recruitment site, cancer stage, age at cancer diagnosis, dates of cancer diagnosis, and randomization. Cox proportional hazards regression models, stratified on case-control pair, were used to assess the associations. Insulin, IGFBP-1, IGFBP-3, leptin, and adiponectin did not significantly predict recurrence of breast cancer. IGF1 was positively, but not significantly, associated with recurrence (hazard ratio (HR): 1.33 (95% confidence interval (CI) 0.98-1.81)) in the unadjusted analyses. Adjusting for menopausal status and tamoxifen use attenuated the HR to 1.07 (95% CI 0.76-1.40). Analyses of case-control pairs with discordant tamoxifen use show opposing HR: IGF1 predicts higher risk of recurrence if cases did not receive tamoxifen treatment. In conclusion, no significant association was found between IGF1 levels, or other related factors, and risk of additional breast cancer among breast cancer survivors. Tamoxifen can confound analysis of IGF1 and recurrence. This supports re-evaluating significance of IGF1 to breast cancer recurrence.

Original languageEnglish (US)
Pages (from-to)235-244
Number of pages10
JournalEndocrine-Related Cancer
Volume18
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Breast Neoplasms
Tamoxifen
Recurrence
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Adiponectin
Leptin
Survivors
Healthy Diet
Confidence Intervals
Insulin
Neoplasms
Random Allocation
Proportional Hazards Models
Carrier Proteins
Hormones
Incidence
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Al-Delaimy, W. K., Flatt, S. W., Natarajan, L., Laughlin, G. A., Rock, C. L., Gold, E. B., ... Pierce, J. P. (2011). IGF1 and risk of additional breast cancer in the WHEL study. Endocrine-Related Cancer, 18(2), 235-244. https://doi.org/10.1530/ERC-10-0121

IGF1 and risk of additional breast cancer in the WHEL study. / Al-Delaimy, Wael K.; Flatt, Shirley W.; Natarajan, Loki; Laughlin, Gail A.; Rock, Cheryl L.; Gold, Ellen B; Caan, Bette J.; Parker, Barbara A.; Pierce, John P.

In: Endocrine-Related Cancer, Vol. 18, No. 2, 04.2011, p. 235-244.

Research output: Contribution to journalArticle

Al-Delaimy, WK, Flatt, SW, Natarajan, L, Laughlin, GA, Rock, CL, Gold, EB, Caan, BJ, Parker, BA & Pierce, JP 2011, 'IGF1 and risk of additional breast cancer in the WHEL study', Endocrine-Related Cancer, vol. 18, no. 2, pp. 235-244. https://doi.org/10.1530/ERC-10-0121
Al-Delaimy WK, Flatt SW, Natarajan L, Laughlin GA, Rock CL, Gold EB et al. IGF1 and risk of additional breast cancer in the WHEL study. Endocrine-Related Cancer. 2011 Apr;18(2):235-244. https://doi.org/10.1530/ERC-10-0121
Al-Delaimy, Wael K. ; Flatt, Shirley W. ; Natarajan, Loki ; Laughlin, Gail A. ; Rock, Cheryl L. ; Gold, Ellen B ; Caan, Bette J. ; Parker, Barbara A. ; Pierce, John P. / IGF1 and risk of additional breast cancer in the WHEL study. In: Endocrine-Related Cancer. 2011 ; Vol. 18, No. 2. pp. 235-244.
@article{e21ca76af8ba4a81a11bdd4bb250bfe3,
title = "IGF1 and risk of additional breast cancer in the WHEL study",
abstract = "IGF1, IGF-binding protein-3 (IGFBP-3), IGFBP-1, insulin, leptin, and adiponectin have been inconsistently associated with breast cancer incidence. We explore how these factors are related to breast cancer recurrence and how tamoxifen treatment is related to IGF1 levels among breast cancer survivors in the Women's Healthy Eating and Living (WHEL) study. A nested case-control design was used to match breast cancer cases (who had an additional breast cancer event) to controls. Baseline blood samples from 510 matched cases and controls were analyzed for IGF1 levels; a subset of 188 pairs were analyzed for five other hormones and binding proteins. Median follow-up was 7.3 years. Matching was on recruitment site, cancer stage, age at cancer diagnosis, dates of cancer diagnosis, and randomization. Cox proportional hazards regression models, stratified on case-control pair, were used to assess the associations. Insulin, IGFBP-1, IGFBP-3, leptin, and adiponectin did not significantly predict recurrence of breast cancer. IGF1 was positively, but not significantly, associated with recurrence (hazard ratio (HR): 1.33 (95{\%} confidence interval (CI) 0.98-1.81)) in the unadjusted analyses. Adjusting for menopausal status and tamoxifen use attenuated the HR to 1.07 (95{\%} CI 0.76-1.40). Analyses of case-control pairs with discordant tamoxifen use show opposing HR: IGF1 predicts higher risk of recurrence if cases did not receive tamoxifen treatment. In conclusion, no significant association was found between IGF1 levels, or other related factors, and risk of additional breast cancer among breast cancer survivors. Tamoxifen can confound analysis of IGF1 and recurrence. This supports re-evaluating significance of IGF1 to breast cancer recurrence.",
author = "Al-Delaimy, {Wael K.} and Flatt, {Shirley W.} and Loki Natarajan and Laughlin, {Gail A.} and Rock, {Cheryl L.} and Gold, {Ellen B} and Caan, {Bette J.} and Parker, {Barbara A.} and Pierce, {John P.}",
year = "2011",
month = "4",
doi = "10.1530/ERC-10-0121",
language = "English (US)",
volume = "18",
pages = "235--244",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "2",

}

TY - JOUR

T1 - IGF1 and risk of additional breast cancer in the WHEL study

AU - Al-Delaimy, Wael K.

AU - Flatt, Shirley W.

AU - Natarajan, Loki

AU - Laughlin, Gail A.

AU - Rock, Cheryl L.

AU - Gold, Ellen B

AU - Caan, Bette J.

AU - Parker, Barbara A.

AU - Pierce, John P.

PY - 2011/4

Y1 - 2011/4

N2 - IGF1, IGF-binding protein-3 (IGFBP-3), IGFBP-1, insulin, leptin, and adiponectin have been inconsistently associated with breast cancer incidence. We explore how these factors are related to breast cancer recurrence and how tamoxifen treatment is related to IGF1 levels among breast cancer survivors in the Women's Healthy Eating and Living (WHEL) study. A nested case-control design was used to match breast cancer cases (who had an additional breast cancer event) to controls. Baseline blood samples from 510 matched cases and controls were analyzed for IGF1 levels; a subset of 188 pairs were analyzed for five other hormones and binding proteins. Median follow-up was 7.3 years. Matching was on recruitment site, cancer stage, age at cancer diagnosis, dates of cancer diagnosis, and randomization. Cox proportional hazards regression models, stratified on case-control pair, were used to assess the associations. Insulin, IGFBP-1, IGFBP-3, leptin, and adiponectin did not significantly predict recurrence of breast cancer. IGF1 was positively, but not significantly, associated with recurrence (hazard ratio (HR): 1.33 (95% confidence interval (CI) 0.98-1.81)) in the unadjusted analyses. Adjusting for menopausal status and tamoxifen use attenuated the HR to 1.07 (95% CI 0.76-1.40). Analyses of case-control pairs with discordant tamoxifen use show opposing HR: IGF1 predicts higher risk of recurrence if cases did not receive tamoxifen treatment. In conclusion, no significant association was found between IGF1 levels, or other related factors, and risk of additional breast cancer among breast cancer survivors. Tamoxifen can confound analysis of IGF1 and recurrence. This supports re-evaluating significance of IGF1 to breast cancer recurrence.

AB - IGF1, IGF-binding protein-3 (IGFBP-3), IGFBP-1, insulin, leptin, and adiponectin have been inconsistently associated with breast cancer incidence. We explore how these factors are related to breast cancer recurrence and how tamoxifen treatment is related to IGF1 levels among breast cancer survivors in the Women's Healthy Eating and Living (WHEL) study. A nested case-control design was used to match breast cancer cases (who had an additional breast cancer event) to controls. Baseline blood samples from 510 matched cases and controls were analyzed for IGF1 levels; a subset of 188 pairs were analyzed for five other hormones and binding proteins. Median follow-up was 7.3 years. Matching was on recruitment site, cancer stage, age at cancer diagnosis, dates of cancer diagnosis, and randomization. Cox proportional hazards regression models, stratified on case-control pair, were used to assess the associations. Insulin, IGFBP-1, IGFBP-3, leptin, and adiponectin did not significantly predict recurrence of breast cancer. IGF1 was positively, but not significantly, associated with recurrence (hazard ratio (HR): 1.33 (95% confidence interval (CI) 0.98-1.81)) in the unadjusted analyses. Adjusting for menopausal status and tamoxifen use attenuated the HR to 1.07 (95% CI 0.76-1.40). Analyses of case-control pairs with discordant tamoxifen use show opposing HR: IGF1 predicts higher risk of recurrence if cases did not receive tamoxifen treatment. In conclusion, no significant association was found between IGF1 levels, or other related factors, and risk of additional breast cancer among breast cancer survivors. Tamoxifen can confound analysis of IGF1 and recurrence. This supports re-evaluating significance of IGF1 to breast cancer recurrence.

UR - http://www.scopus.com/inward/record.url?scp=79953172901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953172901&partnerID=8YFLogxK

U2 - 10.1530/ERC-10-0121

DO - 10.1530/ERC-10-0121

M3 - Article

C2 - 21263044

AN - SCOPUS:79953172901

VL - 18

SP - 235

EP - 244

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 2

ER -